$5.7 Million PSTV Funding

by | Feb 18, 2025 | GBM, LM, PBC, Uncategorized

Plus Therapeutics Secures $5.7 Million in Funding to Advance Cancer Research #PSTV News: Plus Therapeutics has successfully closed a private placement with $3.7 million in upfront proceeds and received a $2.0 million advance payment from the Cancer Prevention and...

OSU: New ReSPECT-GBM Site

by | Feb 4, 2025 | GBM

New Clinical Trial Site Now Enrolling – OSUCCC-James Joins ReSPECT-GBM! We are excited to announce that The Ohio State University Comprehensive Cancer Center – James (OSUCCC – James) has joined our ReSPECT-GBM Clinical Trial as a new investigation site, with Principal...

#WorldCancerDay2025

by | Feb 4, 2025 | GBM, LM, PBC, Uncategorized

Honoring Progress and Hope on World Cancer Day 🔬 Today is #WorldCancerDay, a day dedicated to raising awareness, advancing research, and supporting those affected by cancer. At Plus Therapeutics, we recognize the unwavering dedication of patients, caregivers, and...

Thank You to Our Patients!

by | Feb 1, 2025 | GBM, LM, PBC, Uncategorized

A Heartfelt Thank You to Our ReSPECT-GBM & ReSPECT-LM Clinical Trial Participants To every patient who has participated in the ReSPECT-GBM and ReSPECT-LM clinical trials: THANK YOU! 💙 Your courage and commitment are helping advance critical research for recurrent...

ReSPECT-GBM Closes Phase 1

by | Jan 14, 2025 | GBM

ReSPECT-GBM Clinical Trial Update: Phase 2 Enrollment Now Open We are excited to announce that enrollment for the Phase 1 ReSPECT-GBM clinical trial is complete! We are actively enrolling patients for Phase 2 of the trial, which focuses on treating recurrent...